A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA ... of Nubeqa in combination with androgen deprivation therapy (ADT) for the treatment of patients ...

Androgen deprivation is the mainstay of therapy of advanced prostate cancer ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

and accounts for men who have advanced disease but whose tumours still remain sensitive to treatment with older androgen deprivation therapy (ADT) drugs that lower testosterone. Xtandi ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

Although treatments like androgen deprivation therapy have been effective for early ... Cisplatin, a widely used anticancer drug, has been used in combination therapies but its use is limited ...

A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new ...

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...